Nobu Hospitality Brings Iconic Luxury Lifestyle to Historic Krakw
Introducing Nobu's First Residential Community in Eastern Europe NEW YORK, June 5,…
MemeCore Announces Strategic Entry into South Korea with Acquisition of KOSDAQ-Listed Company
SEOUL, South Korea, June 5, 2025 /PRNewswire/ -- MemeCore, the world's first…
Olympism365 Summit day one: first concrete commitments made for a sustainable future through sport
04 June 2025 - The Olympism365 Summit: Sport for a Better World, hosted by…
Seoul Releases Global Tourism Campaign Featuring Star Chef Edward Lee
Seoul Tourism Organization to globally launch promotional videos featuring star Chef Edward…
Ned Introduces Spotlight, a Lightweight Solution for Instant Cash Flow Insight
Spotlight delivers real-time cash flow visibility so lenders can reduce risk, cut…
GRVT Introduces Retail Price Improvement Orders, Bringing Proven TradFi Execution Benefits Onchain
SINGAPORE, June 4, 2025 /PRNewswire/ -- GRVT, the world's first licensed onchain…
NYSE Content Advisory: NYSE, Money20/20, FINTECH.TV, and Cheddar create “Taking Stock”
NEW YORK, June 3, 2025 /PRNewswire/ -- The New York Stock Exchange…
WASHINGTON FREEDOM ANNOUNCES MULTI-YEAR PARTNERSHIP WITH CLOVER
Clover joins Washington Freedom as Official Partner and Kit Sponsor to elevate…
![Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]](https://i0.wp.com/ml-eu.globenewswire.com/media/NjEzMmQ4NzAtZTBkMS00ZDhhLTkyYjgtOGM3YzY1ZWM5M2U5LTEwMTQyODItMjAyNS0wNi0wMi1lbg==/tiny/Sandoz-International-GmbH.png?w=420&resize=420,280&ssl=1 "Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]")
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA…
Hydreight Reports 34% Year-Over-Year Q1 Revenue Growth, Improvement in Bottom Line Results, and Delivers Strong Performance Across Verticals
“It was an outstanding quarter. We exceeded our Q1 projections with approximately…